Ecuador vs Oman: Access to anti-retroviral drugs, female
Ecuador
75.0%
in 2024
Oman
76.0%
in 2024
Ecuador rank
67th
Oman rank
64th
Access to anti-retroviral drugs, female over time
- Ecuador
- Oman
How they compare
Oman currently reports 76.0% against 75.0% in Ecuador, a difference of 1.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Oman ahead.
Ecuador ranks 67th and Oman ranks 64th of 141 countries.
Across the 3 decades both report, Ecuador averaged higher in 1 and Oman in 2.
Head to head by decade
| Decade | Ecuador | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.3% | 18.3% | 13.0% | Oman |
| 2010s | 38.7% | 55.5% | 16.8% | Oman |
| 2020s | 71.6% | 71.0% | 0.6% | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Ecuador or Oman?
- Oman, at 76.0% against 75.0% in Ecuador as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Ecuador and Oman?
- 1.0%, with Oman ahead.
- How many years of comparable data are there for Ecuador and Oman?
- 25 years are reported by both, from 2000 to 2024.
- How do Ecuador and Oman rank globally for access to anti-retroviral drugs, female?
- Ecuador ranks 67th and Oman ranks 64th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.